Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cell based assays in drug development for biopharmaceuticals--IIR's Second Annual Conference.

Keller S.

IDrugs. 2006 Dec;9(12):841-5. No abstract available.

PMID:
17139570
2.

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.

Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E.

J Immunol Methods. 2007 Apr 10;321(1-2):1-18. Epub 2007 Jan 12. Review.

PMID:
17307199
3.

Quality by design for biopharmaceuticals.

Rathore AS, Winkle H.

Nat Biotechnol. 2009 Jan;27(1):26-34. doi: 10.1038/nbt0109-26. No abstract available.

PMID:
19131992
4.
5.

Conference Report: Analytical challenges in the qualification and validation of pharmacodynamic biomarkers.

Houghton R, Chamberlain J.

Bioanalysis. 2011 May;3(9):945-8. doi: 10.4155/bio.11.90.

6.

Biological assays: their role in the development and quality control of recombinant biological medicinal products.

Mire-Sluis AR, Gerrard T, Das RG, Padilla A, Thorpe R.

Biologicals. 1996 Dec;24(4):351-62. Review. No abstract available.

PMID:
9088552
8.
9.
10.
11.

Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay.

Reder S, Riffelmann M, Becker C, Wirsing von König CH.

Clin Vaccine Immunol. 2008 May;15(5):744-9. doi: 10.1128/CVI.00225-07. Epub 2008 Mar 5.

12.

Physicochemical and biological assays for quality control of biopharmaceuticals: interferon alpha-2 case study.

Silva MM, Lamarre B, Cerasoli E, Rakowska P, Hills A, Bailey MJ, Wheeler JX, Burns CJ, Gaines-Das RE, Jones C, Robinson CJ.

Biologicals. 2008 Nov;36(6):383-92. doi: 10.1016/j.biologicals.2008.06.003. Epub 2008 Aug 8.

PMID:
18691904
13.

Laboratory automation of high-quality and efficient ligand-binding assays for biotherapeutic drug development.

Wang J, Patel V, Burns D, Laycock J, Pandya K, Tsoi J, DeSilva B, Ma M, Lee J.

Bioanalysis. 2013 Jul;5(13):1635-48. doi: 10.4155/bio.13.141.

PMID:
23822127
14.

Celiac disease screening by immunochromatographic visual assays: results of a multicenter study.

Baviera LC, Aliaga ED, Ortigosa L, Litwin N, Peña-Quintana L, Méndez V, González MV, López-Manzanares JM, Méndez E, Koninckx CR.

J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):546-50.

PMID:
18030231
15.
16.

Global Follow-On Biologics--IBC's Fifth Annual Conference. 10-11 December 2007, Reston, VA, USA.

Wheelwright SM.

IDrugs. 2008 Feb;11(2):94-6. No abstract available.

PMID:
18240091
17.

Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo.

Ando H, Matsushita T, Wakitani M, Sato T, Kodama-Nishida S, Shibata K, Shitara K, Ohta S.

Biol Pharm Bull. 2008 Sep;31(9):1739-44.

18.

Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.

Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D.

Ann Neurol. 2008 Sep;64(3):332-43. doi: 10.1002/ana.21450.

PMID:
18825674
19.

Biotherapies: are they just like any other drugs?

Paintaud G, Tonelli D, Postaire E; Round Table No 5, Giens XXII.

Therapie. 2007 May-Jun;62(3):229-39. Epub 2007 Sep 6. Review. English, French.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk